Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


The Campaign Against Drug Pricing: Candidates Can Only Hope Voters React As Strongly As Wall Street

This article was originally published in RPM Report

Executive Summary

Wall Street remains hypersensitive to threats from Washington or the campaign trail to take action to limit prescription drug pricing. But it is still hard to see why the threat is any greater because the Clinton campaign has a “plan” to address the issue.


Related Content

Trump’s Election Could Bring ‘Best Of Times’ For Pharma
Value Vs. Values: ICER’s Review Of Opioid Abuse-Deterrent Formulations
Revisionist History On Health Care Reform Deal
Insurance Restructuring or Co-pay Caps? Testing Nuanced Messages In Charged Pricing Debate
Repatha and Praluent Launches Earn Praise From Express Scripts; Will Investors Applaud As Well?
Biopharma Quarterly Dealmaking Statistics, Q3 2015
When Empty Threats Work: “Price Negotiation” In White House Budget Spooks Wall Street
Washington Threatens; Wall Street Reacts
FDA’s Mermaid Problem: Makena and Pharmaceutical Half-Breeds
Putting the Bully in the Bully Pulpit: The Democrats' Plan to Cut Drug Prices


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts